Modafinil
- Generic Name
- Modafinil
- Brand Names
- Provigil
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15NO2S
- CAS Number
- 68693-11-8
- Unique Ingredient Identifier
- R3UK8X3U3D
- Background
Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactiva...
- Indication
To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Fatigue, Major Depressive Disorder (MDD), Narcolepsy, Obstructive Sleep Apnea (OSA), Shift-work related sleep disturbance
- Associated Therapies
- -
Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC)
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT00943176
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)
- Conditions
- Interventions
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT00917748
- Locations
- 🇦🇺
Sanofi-Aventis Administrative Office, Macquarie Park, Australia
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies
- First Posted Date
- 2009-06-09
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 27
- Registration Number
- NCT00916253
- Locations
- 🇫🇷
AP-HP - Hôpital de l'Hôtel-Dieu, Paris, France
🇫🇷GENNPHASS - CHU de Bordeaux, Bordeaux, France
The Effects of Modafinil to Counteract the Adverse Metabolic Consequences of Sleep Restriction
- Conditions
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2009-05-08
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00895570
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
Modafinil for Methamphetamine Dependence
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 9
- Registration Number
- NCT00859573
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Pharmacotherapy & CM for Opioid and Cocaine Dependence
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Yale University
- Target Recruit Count
- 91
- Registration Number
- NCT00838981
- Locations
- 🇺🇸
Department of Veterans Affairs, West Haven, Connecticut, United States
Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Manhattan Psychiatric Center
- Registration Number
- NCT00838227
Modafinil for the Treatment of Fatigue in Lung Cancer V9.0
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2013-08-19
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 208
- Registration Number
- NCT00829322
- Locations
- 🇬🇧
Stoke Mandeville Hospital, Aylesbury, United Kingdom
🇬🇧Great Western Hospital, Swindon, United Kingdom
🇬🇧Christie Hospital, Manchester, United Kingdom
Effects of Modafinil in Methamphetamine Dependence
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 40
- Registration Number
- NCT00751023
- Locations
- 🇺🇸
Behavioral Health Services of Pickens County, Pickens, South Carolina, United States
Study of Modafinil to Treat Fatigue in Persons With Traumatic Brain Injury
- Conditions
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2010-06-14
- Lead Sponsor
- Craig Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00702637
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.